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2 
Abstract 17 
Objective To characterise, as a clinical study, the pharmacokinetics and 18 
pharmacodynamics and describe the hypnotic effect of the neurosteroid alfaxalone (3α-19 
hydroxy-5 α-pregnane-11, 20-dione) formulated with 2-hydroxypropyl-β-cyclodextrin 20 
in male and female rats.  21 
Study design Prospective, experimental laboratory study. 22 
Animals Twelve (six male and six female) adult, aged matched Sprague Dawley rats. 23 
Methods Surgery and instrumentation was performed under isoflurane anaesthesia in an 24 
oxygen/nitrous oxide mixture (1:2) and local anaesthetic infiltration. All animals 25 
received a loading dose (1.67 mg kg -1 minute -1) for 2.5 minutes followed by a constant 26 
rate infusion (0.75 mg kg -1 minute -1) for 120 minutes of alfaxalone.  Isoflurane and 27 
nitrous oxide was discontinued 2.5 minutes after the alfaxalone infusion started. 28 
Cardiorespiratory variables (heart rate, respiratory rate, arterial blood pressure, end tidal 29 
carbon dioxide tension) and clinical signs of anaesthetic depth were evaluated 30 
throughout anaesthesia. Carotid artery blood samples were collected at strategic time 31 
points for blood gas analysis, haematology and biochemistry and plasma concentrations 32 
of alfaxalone. Plasma samples were assayed using liquid chromatography-mass 33 
spectrometry (LC/MS). 34 
Results There were significant differences between the sexes for plasma clearance (p = 35 
0.0008), half-life (p = 0.0268) and mean residence time (p = 0.027). Mean arterial blood 36 
pressure was significantly higher in the male rats (p = 0.0255).  37 
Conclusions and clinical relevance This study confirms alfaxalone solubilized in a 2-38 
hydroxypropyl-β-cyclodextrin provides excellent total intravenous anaesthesia in rats. 39 
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Sex-based differences in pharmacokinetics and pharmacodynamics were demonstrated 40 
and must be considered when designing biomedical research models using alfaxalone. 41 
 42 
Keywords alfaxalone,  anaesthetics, intravenous, rat, steroid,  43 
  44 
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4 
Introduction 45 
Alfaxalone is a neuroactive steroid that modulates neurotransmission through 46 
interaction with a steroid recognition site on the GABAA receptor complex causing a 47 
positive allosteric modulation of the ligand gated chloride channel resulting in 48 
inhibition of neuronal excitability (Harrison & Simmonds 1984; Turner et al. 1989). 49 
Such agents therefore have roles in anaesthesia, epilepsy, anxiety, insomnia, migraine 50 
and drug dependence (Rupprecht & Holsboer 1999). Alfaxalone had been used as an 51 
anaesthetic induction agent in humans and veterinary species for almost half a century 52 
but anaphylactoid reactions attributed to the polyethoxylated castor oil (Cremophor EL) 53 
vehicle (Tammisto et al. 1973) made its use redundant. Subsequent formulations of 54 
alfaxalone incorporating a cyclodextrin have hitherto been devoid of the previous side 55 
effects and Alfaxan (alfaxalone dissolved in 2-hydroxypropyl-β-cyclodextrin) is now 56 
registered for induction and maintenance of anaesthesia in dogs and cats and has been 57 
used in horses (Goodwin et al. 2011) sheep (Andaluz et al. 2012; del Mar Granados et 58 
al. 2012) rabbits (Navarrete-Calvo et al. 2014) and other more exotic species (Bouts & 59 
Karunaratna 2011; McMillan & Leece 2011; Bauquier et al. 2013; Kischinovsky et al. 60 
2013; Knotek et al. 2013; Villaverde-Morcillo et al. 2014).  61 
The use of alfaxalone in biomedical research and clinical veterinary medicine is gaining 62 
popularity as it may offer some selective advantages over other anaesthetic 63 
combinations in terms of safety, reflex suppression, cardiopulmonary depression, 64 
interaction with receptors involved in pain pathways/modulation and pain on injection 65 
(Child et al. 1972; Michou et al. 2012; Santos González et al. 2013) but may also offer 66 
additional advantages in influencing CNS development and myelination (Yawno et al. 67 
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2014). Alfaxalone has been popular for neuroendocrine studies for its sparing of various 68 
forebrain functions (Sarkar et al. 1976; Sherwood et al. 1980). Human trials of 69 
alphaxalone in cyclodextrin are currently underway (Monagle et al. 2015).  70 
The majority of animals used in basic science pain research however are young healthy 71 
male laboratory rodents, and indeed it has been suggested that a more heterogeneous 72 
and diverse population be used to improve the translational relevance to a human 73 
population (Mogil 2009). The inclusion of female rodents is to be encouraged despite 74 
the additional complexities that the variability of the oestrous cycle and sexual 75 
dimorphism poses; well-designed studies can include both sexes without needless 76 
increase in animal numbers (Clayton & Collins 2014). With respect to alfaxalone usage, 77 
the pharmacokinetics of a single intravenous (IV) dose have been defined in dogs (Ferré 78 
et al. 2006) cats (Whittem et al. 2008b; Muir et al. 2009) female rats (Lau et al. 2013) 79 
and male rats after a 5 minute infusion (Visser et al. 2002). The novelty and primary 80 
aim of this study was therefore to characterise the pharmacokinetics, 81 
pharmacodynamics and hypnotic characteristics of a constant rate infusion of alfaxalone 82 
in male versus female rats. 83 
 84 
Materials and methods 85 
This study was performed in accordance with Project Licence PPL30/3156 issued under 86 
the Animal (Scientific) Procedures Act 2013 (EU Directive 2010/63/EU) and local 87 
ethics committee as part of a larger study investigating nociceptive withdrawal reflexes 88 
and diffuse noxious inhibitory control. This study is reported in accordance with the 89 
ARRIVE guidelines (Kilkenny et al. 2014). 90 
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Animals 91 
Twelve (9-12 week old) Sprague Dawley rats, six male (397 ± 16 g) and six female 92 
(286 ± 20 g) (Charles River Laboratories, Margate, UK) were used. Animals were 93 
housed in single sex groups of four, given access to food (Teklad 2018, Harlan) and tap 94 
water ad libitum and maintained on a 12-hour light/dark cycle. All experiments started 95 
at 10:00 h each day.  96 
 97 
General anaesthesia 98 
Anaesthesia was induced using 3% isoflurane (Isoflo; Abbott, UK) in oxygen and 99 
nitrous oxide mixture (1:2). Once the rat had lost its righting reflex, it was transferred to 100 
a heating blanket (Harvard Apparatus Ltd., UK) coupled to a rectal probe for 101 
maintenance of body temperature (37.5 ± 0.5°C). Anaesthesia was maintained using 102 
2.00-2.25% (vaporizer setting) isoflurane in oxygen/nitrous oxide delivered via a 103 
nosecone. Lidocaine 2% (Lignol; Dechra, UK) 3 mg kg-1 was infiltrated subcutaneously 104 
prior to skin and sternohyoid incision. The trachea was surgically cannulated using 105 
polyethylene 2.42mm O.D. tubing (Fisher Scientific, UK). Respiratory rate and effort 106 
was assessed by observing chest excursion and measuring end tidal carbon dioxide 107 
(CapStar 100, Linton, Diss, UK). In animals exhibiting respiratory depression as judged 108 
by a low respiratory rate and rising end tidal carbon dioxide values, intermittent positive 109 
pressure ventilation was initiated (Harvard 683 ventilator, Harvard Apparatus, UK) at 110 
60-80 breaths minute-1 to maintain end tidal carbon dioxide at 35-45 mmHg (4.67-6.00 111 
kPa). The left jugular vein was surgically cannulated using 0.63 mm O.D. polyethylene 112 
tubing (Fisher Scientific) for administration of alfaxalone. The left carotid artery was 113 
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7 
surgically cannulated using 1mm O.D. polyethylene tubing (Fisher Scientific) to 114 
monitor arterial blood pressure and for sampling. Arterial blood pressure was monitored 115 
by an arterial pressure transducer (SensoNor 840; SensoNor, Norway) and recorded 116 
using a PC running Spike2 software (CED Ltd, UK). Heart rate was recorded via two 25 117 
gauge needles inserted subcutaneously on the lateral sides of the thoracic wall. The 118 
electrocardiogram signal was amplified and used to trigger an instant rate meter 119 
(Neurolog NL253, Digitimer, UK) and again recorded using Spike2 software. 120 
An infusion of alfaxalone (Alfaxan, Jurox, UK) was started at time 0 at a loading dose 121 
of 1.67 mg kg-1 minute-1 for 2.5 minutes followed by a constant rate infusion (0.75 mg 122 
kg-1 minute-1) for the remainder of the electrophysiological experiment using a 123 
calibrated syringe driver (SP100iz, WPI, UK). The isoflurane and nitrous oxide were 124 
stopped 2.5 minutes after starting the alfaxalone infusion. Arterial blood was withdrawn 125 
from the carotid cannula into lithium heparin and placed on ice. Blood samples (200µl) 126 
were collected at baseline (prior to alfaxalone), end of loading dose, and at 10, 30, 60, 127 
90, 120 minutes. Arterial blood gases, biochemistry and haematology parameters (pH, 128 
pCO2, pO2, bicarbonate, sodium, potassium, chloride, calcium, glucose, lactate and 129 
creatinine concentrations) were also measured (EPOC, Woodley Instrumentation, 130 
Bolton, Lancashire, UK). All rats received an equal volume of balanced electrolyte 131 
solution after sampling (Vetivex 11 (Hartmann’s); Dechra, UK). Samples were 132 
centrifuged (4000g for 10 minutes) within 30 minutes of collection. Plasma was 133 
harvested and stored at -20°C until determination of plasma alfaxalone concentration. 134 
The hypnotic characteristics of the anaesthetic were evaluated by monitoring paw 135 
withdrawal reflex in response to pinch, corneal reflex in response to light brushing, 136 
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8 
spontaneous blinking and gross purposeful movement and cardiopulmonary parameters. 137 
Following the pharmacokinetic study, a separate electrophysiological study was 138 
performed, EMG responses were recorded from tibialis anterior, biceps femoris, and 139 
medial gastrocnemius muscles during electrical plantar hind paw stimulation of the toes 140 
and heel, before and after a conditioning injection of capsaicin into either the 141 
contralateral forelimb to study diffuse noxious inhibitory controls (DNIC) or the 142 
ipsilateral hind limb to investigate central sensitization and reflex facilitation (Harris & 143 
Clarke 2003). Data from this part of the study were not included in this paper but 144 
informed the subjective assessment of response to noxious stimuli during alfaxalone 145 
anaesthesia. At the end of the experiments animals were euthanised by IV injection of 146 
pentobarbitone (Pentobarbital; Ayrton Saunders Ltd, UK) followed by cervical 147 
dislocation (as required by UK Home Office regulations). All female rats underwent 148 
vaginal swabbing to characterise vaginal smear cell types. Slides were examined under 149 
x40 and then x100 magnifications (BH2 microscope, Olympus, UK) after staining with 150 
modified Giemsa (Diff Quik, Vet Direct, UK) and cell types and numbers were 151 
recorded.  152 
 153 
Sample analyses 154 
Samples were analyzed for alfaxalone using a LCMS/MS method. Methanolic standard 155 
curve and quality control (QC) spiking solutions were produced for alfaxalone from 156 
separate accurate weighings of solid compound. Standards and QCs were prepared by 157 
spiking 10 µl spike solution into a solution of 20 µl plasma + 30 µl water + 40 µl 158 
methanol + 150 µl methanol containing 1000 nM tolbutamide as internal standard. 159 
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Plasma standard curves were prepared from 100 – 5000 ng mL-1 and QCs were prepared 160 
for 250 and 2500 ng mL-1. Blank male or female plasma was used for the standards and 161 
QC solutions (Charles River, UK). The plasma samples were prepared by adding 30 µl 162 
water + 50 µl methanol + 150 µl methanol containing 1000 nM tolbutamide as internal 163 
standard to 20 µl plasma. Samples, standards and QCs were then mixed and stored in a 164 
freezer at -20°C for a minimum of 120 minutes prior to centrifugation at 4000g for 20 165 
minutes. The samples were extracted and analyzed using a Micromass Quattro Premier 166 
mass spectrometer incorporating an Acquity autosampler (Waters, UK). An ACE Excel 167 
2 C18-AR 50 x 2.1mm column was used with the following LC conditions: Solvent A = 168 
Water + 0.1% Formic Acid, Solvent B = Methanol + 0.1% Formic Acid, Flow rate = 0.8 169 
mL minute-1, column temperature = 60°C. LC gradient went from 95 % solvent A:5 % 170 
solvent B to 5 % solvent A:95 % solvent B over a 1.5 minute interval. The MS/MS 171 
method used electrospray positive mode with a 333.16 ˃107.01 transition for the 172 
detection of alfaxalone. The lower limit of quantification (LLOQ) was 100 ng mL-1. The 173 
coefficient of variation at LLOQ was <8% and <16% for other concentration levels. All 174 
samples were run in triplicate. Two separate LC/MS/MS runs were performed for the 175 
male and female samples, respectively.  176 
Samples were analysed within 28 days of collection based on data from analytical 177 
validation study file supporting stability of alfaxalone in rat plasma at -20 ° for 30 days 178 
(Jurox 2010). 179 
 180 
Pharmacokinetic analyses 181 
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Pharmacokinetic analysis was carried out using Phoenix WinNonlin 6.3 (Pharsight, 182 
Sunnyvale, CA, USA). The pharmacokinetic parameters (clearance, volume of 183 
distribution and half life) for each individual rat were estimated according to best fit 184 
from an IV infusion one compartmental pharmacokinetic model, based on previous 185 
published data (Lau et al. 2013) showing a single exponential decay, with appropriate 186 
weighting for best fit. The appropriate weighting for best fit in this study was based on 187 
examination of the residuals showing random scatter around predicted values using 1/y^ 188 
weighting by 1/reciprocal of the predicated value. 189 
 190 
Statistical Analyses 191 
Statistical tests were performed using GraphPrism (GraphPad Software, CA, USA) 192 
version 6. The pharmacokinetic parameters for log transformed parameter data for both 193 
genders were compared using an unpaired, two tailed Student’s t-test and a p value of 194 
<0.05 was considered significant. Data are reported as mean ± standard deviation (SD) 195 
unless stated otherwise. 196 
Cardiopulmonary data were collected continuously, and analyzed at the 197 
pharmacokinetic time points. The normality assumptions were tested with Kolmogorov-198 
Smirnov or Shapiro-Wilk tests. The differences in heart rate, mean/systolic/diastolic 199 
arterial blood pressure, blood gas variables, lactate, glucose and electrolytes between 200 
genders were compared using an unpaired t-test. For a more detailed analysis of 201 
changes over time, these variables were also analyzed by two-way repeated-202 
measures ANOVA (one factor repetition) for the time points between baseline anaesthesia 203 
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and 120 minutes after alfaxalone infusion with Sidak’s correction for multiple 204 
comparisons.  205 
 206 
Results 207 
Anaesthetic induction and instrumentation were completed without difficulty in all 208 
animals. All animals underwent a total of 230 ± 20 minutes of alfaxalone anaesthesia 209 
consisting of a 120 minutes of a PK/PD study followed by an electrophysiology study. 210 
Only results from the former are reported here. 211 
 212 
Pharmacokinetics 213 
The shape of the concentration-time curve following a loading dose and then constant 214 
rate infusion was typical of those observed for anaesthetic induction drugs exhibiting an 215 
initial steep phase after the loading dose followed by a gradual increase until steady 216 
state was achieved. The plasma concentrations were substantially different between the 217 
sexes (Figure 1). 218 
The pharmacokinetic parameters calculated by an IV infusion one compartmental model 219 
are shown in Table 1. Logarithmic transformed data for clearance and t1/2 was 220 
significantly different between the male and female rats by the two-tailed t-test. As 221 
would be expected the MRT was also significantly different between genders.  222 
 223 
Pharmacodynamics 224 
Cardiopulmonary data are presented in Table 2. 225 
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After a 2.5 minute loading dose all rats showed an initial short lived decrease in arterial 226 
blood pressure, heart rate and respiratory rate as a result of concomitant administration 227 
of inhalant and alfaxalone. Within the next 5 minutes following discontinuation of 228 
isoflurane, all rats demonstrated an increase in blood pressure from baseline reading 229 
under isoflurane and nitrous oxide anaesthesia. Blood pressure (mean, systolic, 230 
diastolic), heart rate and respiratory rate at baseline were not significantly different 231 
between male and female rats under isoflurane anaesthesia. 232 
Heart rates remained stable during alfaxalone anaesthesia and there was no significant 233 
difference between the sexes at any time points.  234 
Systolic, mean and diastolic arterial pressures all increased from baseline under 235 
isoflurane anaesthesia, reached a peak (between 60 and 90 minutes) and thereafter 236 
showed a trend of decreasing with time. Mean arterial blood pressure was significantly 237 
different between males and female rats (p = 0.026), however the interaction with time 238 
(p < 0.0001) differed between the genders for mean (and systolic and diastolic) pressure 239 
and makes the interpretation of these data difficult (Fig. 2). Significant differences were 240 
analyzed post hoc using Sidak’ multiple comparison test. Mean arterial blood pressure 241 
was significantly increased compared to baseline in male rats at 30, 60, 90 and 120 242 
minutes from starting the alfaxalone (p < 0.0005), as were systolic and diastolic 243 
pressures. Mean arterial blood pressure was only significantly greater than baseline in 244 
the female rats at 60 minutes. In 4 of 12 animals (2 males and 2 females) 245 
cardiopulmonary depression, indicated by a decrease in blood pressure or respiratory 246 
rate, necessitated discontinuation of the isoflurane and nitrous oxide before the 2.5 247 
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minute time point. Within 60 seconds of discontinuation of the isoflurane and nitrous 248 
oxide, heart rate and blood pressure began to rise in all animals.  249 
All female rats ventilated spontaneously throughout the experiment, whereas 2 of 6 250 
male rats required mechanical ventilation as judged by apnoea, or a rise in end tidal 251 
carbon dioxide coupled with a decrease in respiratory rate and effort.  252 
Blood gas parameters and biochemistry values are presented in Table 3. There were no 253 
significant differences between sexes for these parameters except for pH (p = 0.0027), 254 
which was lower in the female rats in conjunction with higher partial pressures of 255 
carbon dioxide. The clinical significance of this is unknown and of little significance. 256 
Partial pressures of oxygen were different between baseline and subsequent time points, 257 
trending towards higher values under total intravenous anaesthesia compared to 258 
inhalational anaesthesia.  259 
 260 
Hypnotic effect 261 
The plane of anaesthesia was continually evaluated by serial cardiopulmonary 262 
measurements, blood gas analysis and reflex responses.  Subjective evaluation of this 263 
hypnotic effect of the alfaxalone in all 12 rats was excellent. No rats demonstrated gross 264 
purposeful movement or required a change in the infusion rate to improve the plane of 265 
anaesthesia.   266 
 267 
Vaginal smears 268 
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The same investigator read all slides (3 per rat) and evaluated the whole slide to give an 269 
impression of the smear, rather than exact cell counts. Three rats were characterized as 270 
in dioestrus, one in proestrus, one in oestrus, and one in metoestrus. 271 
Discussion 272 
The major finding from this study is that consideration must be given to the dose of 273 
anaesthetic delivered to male and female subjects. Without this interrogation of the 274 
experimental model there remains the danger that studies will be carried out under what 275 
is assumed to be identical ‘planes’ of anaesthesia, when in reality one sex may be more 276 
or less profoundly anaesthetized such that, for example, hormonal or neuroendocrine 277 
responses will be affected.  278 
The data reported here were part of an electrophysiological study investigating diffuse 279 
noxious inhibitory controls of nociceptive withdrawal reflexes and is part of a larger 280 
study of descending control in chronic osteoarthritis, which in humans is more prevalent 281 
in females, and highlights the potential risk that using one sex may contribute to the 282 
failure of Phase 1 trials or misleading conclusions. In many studies, the influence of the 283 
anaesthetic is ignored, or so poorly reported that ensuring a consistent plane of 284 
anaesthesia is impossible. Although rats are frequently used in laboratory studies 285 
involving anaesthesia, it is typically males used to reduce experimental variability 286 
(Zucker & Beery 2010). The limitation of this approach is that basic science intended to 287 
be translated into the human population is potentially compromised by the use of one 288 
sex (Clayton & Collins 2014). This perceived variability in females is often used as a 289 
reason for excluding females from studies. A meta-analysis of 293 studies in which 290 
murine behavioural, morphological, physiological, and molecular traits were monitored 291 
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in both sexes showed variability was not significantly greater in females for any 292 
endpoint but several traits contributed to substantially greater variability in the males in 293 
this analysis, including the influence of group housing (Prendergast et al. 2014). 294 
Commendably, there is a movement towards trying to include more female subjects in 295 
studies.  296 
The small sample size in our study makes it impossible to postulate that differences 297 
within the females are a result of the differences in the oestrous cycle or as a result of 298 
normal variability; nonetheless it demonstrates that if steroid hormones can affect 299 
alfaxalone efficacy, the stage of the oestrous cycle may also contribute. It is possible 300 
that the three female rats requiring additional isoflurane for several minutes between 301 
minute 6 and 10 after commencing the alfaxalone may be a result of the stage of the 302 
oestrous cycle, but this is impossible to prove definitively. 303 
In the research community there remains a collective responsibility for a thoroughness 304 
of reporting anaesthesia conditions in order that the anaesthesia is not ‘the elephant in 305 
the room’.a 306 
 307 
Other species e.g. cats display similar pharmacokinetic characteristics to this rat study 308 
(Whittem et al. 2008a). The characteristic rapid hepatic metabolic clearance of 309 
alfaxalone by the liver has been identified in-vivo and in-vitro in rats (Sear & McGivan 310 
                                                        
a “Elephant in the room” is an English metaphorical idiom for an obvious truth that is either being 
ignored or going unaddressed. The idiomatic expression also applies to an obvious problem or risk no 
one wants to discuss. 
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1980; Sear & McGivan 1981). Gender based differences in drug metabolism are the 311 
primary cause of sex-dependent pharmacokinetics and reflect differences in the 312 
expression of hepatic enzymes active in the metabolism of many extrinsic and intrinsic 313 
chemicals, including cytochrome P450 (Waxman & Holloway 2009). Rodent studies 314 
have identified more than a 1000 genes whose expression is dependent on sex and these 315 
genes modulate liver metabolic function and create sexual dimorphism in liver function 316 
(Tanaka 1999). Differences in bioavailability, distribution, metabolism, and/or excretion 317 
in different sexes are multifactorial and complicated (Soldin & Mattison 2009).  Drug 318 
distribution can also be sex linked, influenced by factors such as body fat, plasma 319 
volume and differential perfusion of organs. However, in this study no significant 320 
difference was recorded between male and female Vss suggesting this was not an issue. 321 
In general, however, sex differences in metabolism are thought to be the primary 322 
determinant of variation in pharmacokinetics and this is most likely the reason for the 323 
differences seen in this study. 324 
 325 
The quality of anaesthesia was subjectively judged as excellent in all rats. Contrary to 326 
previous studies (Brammer et al. 1993), this anaesthetic combination provided very 327 
good conditions, stability and survival beyond 180 minutes. The lower blood pressures 328 
observed in female rats in this study would suggest that these animals were more 329 
profoundly anaesthetized than the males. There was no difference in heart rates between 330 
the groups, and the depth of anaesthesia was not so sufficiently profound as to cause 331 
apnoea in the females. This is likely to be a pharmacokinetic effect as the females’ 332 
clearance of alfaxalone is so much less than in the male rats. The consistency of the 333 
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haematology, biochemistry and blood gas values in all rats demonstrates the stability of 334 
the protocol. Blood gas values are infrequently reported for rodent anaesthetics, in part 335 
due to the technical nature of artery cannulation, and previously the volume of blood 336 
required made repeated sampling impossible due to a deleterious depletion of the blood 337 
volume of the animal. Newer point of care analyzers are able to process much smaller 338 
volumes. Total blood volume removed was well below the limit of 10% blood volume 339 
and this removal of blood in conjunction with a replenishment of balanced electrolyte 340 
solution clearly had no impact on the animals. All biochemistry and haematology values 341 
except chloride were similar to those provided by the supplier of the Sprague Dawley 342 
rats in age-matched subjects. Invariably these samples were analysed with different 343 
machines, but even with slight discrepancies usually seen between laboratories, plasma 344 
chloride values in the study (mmol L-1) (114 ± 2.6 (females) 115 ± 2.7 (males)) and 345 
values in age matched conscious Sprague Dawley rats (109 ± 1.4 (females), 103 ± 1.00 346 
(males) were different. A moderate corrected hyperchloraemia was present (when 347 
measured sodium values were also taken into consideration). The most likely cause was 348 
the administration of normal heparinized saline during cannula placement and through 349 
flushing of the carotid cannula with heparinized saline to maintain patency for sampling 350 
and blood pressure measurement. A concurrent acidosis was not observed, and sodium 351 
values were almost identical between the supplied conscious values and those 352 
measured. The potential deleterious effects of normal saline administration have been 353 
raised (Handy & Soni 2008) and the administration of non-physiological saline and 354 
balanced electrolyte solutions is warranted. The clinical impact of hyperchloraemia is 355 
unknown in this study, but in humans there is an increasing awareness that 356 
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hyperchloraemia and hyperchloraemic acidosis can cause significant clinical 357 
ramifications (Handy & Soni 2008). 358 
 359 
Differences in efficacy of the older alfaxalone steroid (Alphathesin/Althesin) in male 360 
and female rats has been demonstrated, with males requiring four times the dose of 361 
females for surgical anaesthesia and analgesia, and it was concluded that the influence 362 
of sex hormones was responsible for this discrepancy (Fink et al. 1982). However a 363 
recent study disputed this and postulated that differences are more likely a result of the 364 
different formulations of alfaxalone and assay methodologies than differences between 365 
sexes (Lau et al. 2013). Notwithstanding these views it has also been shown that 366 
formulation is hugely influential; the toxicity of alfaxalone in Wistar rats was less in 367 
those animals receiving alfaxalone dissolved in 7-sulfobutyl-ether-β-cyclodextrin 368 
(SBECD) compared to alfaxalone in Cremophor EL (Goodchild et al. 2015). The 369 
current study directly comparing male and female Sprague Dawley rats receiving an 370 
HPCD alfaxan formulation seemingly favours a true sex difference due to 371 
pharmacokinetics, pharmacodynamics or both as the explanation. Sex based studies 372 
using rats anaesthetized with pentobarbitone have also demonstrated differences 373 
(Zambricki & Dalecy 2004). Sex differences have been detected in studies comparing 374 
IP and IV routes in rats (Estes et al. 1990) postulating that the lack of obvious sex 375 
differences with single IV dosing may be a result of the short duration of effect.   376 
Group sizes of 6 were deemed appropriate for evaluating a drug exhibiting within 377 
subject variability of less than 30% coefficient of variation of pharmacokinetic 378 
measures (Rowland & Tozer 2011) and recent studies comparing cardiovascular effects 379 
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of anaesthetic drugs have successfully used 5 rats per group (Bencze et al. 2013). It 380 
should also be noted that the presence of isoflurane and nitrous oxide at the outset of the 381 
loading dose is likely to have affected cardiopulmonary parameters in the very early 382 
stages of the infusion and conclusions drawn about differences at these time points are 383 
likely to be tenuous. However both groups underwent identical protocols so this 384 
influence would have been similar for both groups. The use of an inhalational agent 385 
such as isoflurane with minimal metabolism and rapid elimination ensured that the 386 
period of time from ceasing administration was as short as possible. The maximum 387 
possible duration of initial concurrent administration was 2.5 minutes.  388 
 389 
In summary, there are pharmacokinetic and pharmacodynamic differences with 390 
alfaxalone in cyclodextrin in male and female rats. The plane of anaesthesia provided 391 
by this protocol is stable and clinically indistinguishable between sexes with no 392 
apparent cumulative effect. Half-life, clearance and mean residence time were 393 
significantly different between male and female rats indicating that a sex-linked effect 394 
was present. The protocol in our study provides excellent anaesthesia conditions but 395 
concludes that a dose alteration may be necessary for rat sex-based studies 396 
incorporating alfaxalone. This contrasts to previous published studies, which have 397 
dismissed a sex difference (Ferré et al. 2006; Berry 2015). Population pharmacokinetics 398 
are necessary to further investigate these findings. 399 
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Figure Legends 549 
 550 
Figure 1 Mean (± SD) alfaxalone plasma concentrations (ng mL-1) for 12 Sprague 551 
Dawley rats (6 female, 6 male) after intravenous administration of alfaxalone 1.67 mg 552 
kg -1 minute -1 for 2.5 minutes followed by 0.75 mg  kg -1  minute -1 alfaxalone for 120 553 
minutes using a one compartment infusion model.  554 
 555 
Figure 2 Mean (± SD) arterial blood pressure (MAP) (mmHg) for 12 Sprague Dawley 556 
rats (6 female, 6 male) after intravenous administration of alfaxalone 1.67 mg  kg -1  557 
minute -1 for 2.5 minutes followed by 0.75 mg  kg -1 minute -1 alfaxalone for 120 minutes 558 
using a one compartment infusion model.  559 
 560 
 561 
  562 
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Table 1 Pharmacokinetic parameters for 12 Sprague Dawley rats (6 female, 6 male) 563 
after intravenous administration of alfaxalone at a rate of 1.67 mg kg -1 minute -1 for 2.5 564 
minutes followed by 0.75 mg kg -1 minute-1 for 120 minutes using a one compartment 565 
infusion model.  566 
 567 
Rat ID CL 
(mL 
minute -1 
kg -1) 
T
 ½ 
 
Vdss 
L kg-1 
MRT 
minutes 
Cmax 
mg L-1  
Female 1 66.3 33.8 3.24 48.8 1.3 
Female 2 40.4 29.8 1.74 43.0 2.3 
Female 3 46.9 76.7 5.19 110.7 0.8 
Female 4 58.2 30.9 2.60 44.6 1.6 
Female 5 31.9 69.2 3.19 99.9 1.3 
Female 6 42.3 34.1 2.08 49.2 2.0 
Mean 47.7 45.8 3.00 66.0 1.5 
Sd 8.86 20.7 0.6 30.7 0.6 
Male 1 65.8 52.1 4.94 75.1 0.8 
Male 2 79.9 13.2 1.53 19.1 2.6 
Male 3 78.5 17.3 1.95 24.9 2.0 
Male 4 117.9 10.3 1.75 14.8 2.2 
Male 5 106.2 18.6 2.85 26.8 1.4 
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Male 6 101.2 26.5 3.87 38.3 1.0 
Mean 91.6 23.0 2.82 33.2 1.7 
Sd 19.9 15.3 1.36 22.0 0.7 
P value  0.0008*** 0.0268* 0.710 0.027* 0.780 
 568 
 569 
CL = clearance, t1/2= half life, Vdss = volume of distribution, MRT = mean residence 570 
time, Cmax = maximum plasma concentration 571 
CL, t1/2 and MRT is significantly different between the male and female rats.  572 
Asterisks denote significant difference *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 573 
  574 
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Table 2 Cardiopulmonary parameters for 12 Sprague Dawley rats (6 female, 6 male) after intravenous administration of 575 
alfaxalone at a rate of 1.67 mg kg -1 minute -1  for 2.5 minutes followed by 0.75 mg kg -1 minute-1 for 120 minutes using a one 576 
compartment infusion model.  577 
 578 
Variable Sex -5 2.5 10 30 60 90 120 
MAP 
 
Male 97  ± 7 71 ± 7 110 ± 32* 127± 17**** 138 ± 11**** 135 ± 16**** 132 ± 9**** 
Female 89 ± 13 90 ± 20 110 ± 17 114 ± 18 121 ± 14** 113 ± 23 114 ± 21 
SAP Male 98 ± 8 96 ± 9 132 ± 33** 153 ± 22**** 167 ± 17**** 167 ± 17**** 158 ± 11**** 
Female 108 ± 
12 
111 ± 
17 
127 ± 14 133 ± 15 144 ± 15** 138 ± 25* 138 ± 24* 
DAP Male 69 ± 7 60 ± 9 98 ± 32*
 
114 ± 15***
 
124 ± 11**** 119 ± 19**** 120 ± 8**** 
Female 79 ± 14 79 ± 21 101 ± 19 104 ± 19 109 ± 14* 100 ± 22 101 ± 21 
HR Male 440 ± 442 ± 440 ± 15
 
455 ± 23 447 ± 28
 
438 ± 34 423 ± 23 
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MAP: mean arterial pressure (mmHg); SAP: systolic arterial pressure (mmHg); DAP: diastolic arterial pressure (mmHg); HR: 579 
heart rate (beats per minute); RR: respiratory rate (breaths per minute) 580 
 581 
Baseline (-5 minute) samples were all measured under isoflurane (2% vaporizer setting) in N2O and O2. Data are mean ± SD. 582 
Asterisks denote significant difference from baseline (-5 mins) within a group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 583 
using 2 way ANOVA with multiple comparisons. 584 
  585 
25 28 
Female 440 ± 
31 
440 ± 
31 
436 ± 35 455 ± 23 445 ±22 415 ± 12 422 ± 16 
RR Male 58 ± 12 55 ± 10 56 ± 10 68 ± 10 57 ± 14 65 ± 7 71 ± 9 
Female 56 ± 10 54 ± 7 56 ± 6 55 ± 5 63 ± 5 68 ± 4 69 ± 4 
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Table 3 Measured blood gas variables and clinical biochemistry parameters for 12 Sprague Dawley rats (6 female, 6 male) after 586 
administration of alfaxalone at a rate of 1.67 mg kg -1 min -1 for 2.5 minutes followed by 0.75 mg kg -1 min -1 alfaxalone for 120 587 
minutes using a one compartment infusion model. Data are mean ± SD.   588 
 589 
Variable Sex Minutes relative to the alfaxalone infusion start time 
-5 30 60 90 120 
pH * Male  7.36 ± 0.10 7.42 ± 0.12 7.44 ± 0.08 7.41 ± 0.08 7.40 ± 0.06 
Female  7.36 ± 0.14 7.36 ± 0.14 7.35 ± 0.12 7.32 ± 0.10 7.37 ± 0.08 
PCO2 (mmHg) Male  36 ± 6 35 ± 12 39 ± 4 40 ± 0.4 30 ± 4 
 Female  40 ± 16 44 ± 21 44 ± 16 43 ± 13 37± 7 
PO2   (mmHg) Male  140 ± 13 218 ± 19 249 ± 13 258 ± 16 276  ± 18 
 Female  190 ± 31 318 ± 130 265 ± 54 263 ± 37 219 ± 70 
HCO3  (mmol L-1) Male  23 ± 5 25 ± 2 23 ± 3 23 ± 3 21 ± 3 
 Female  24 ± 4 23 ± 4 22 ± 3 21 ± 3 21 ± 9 
Sodium (mmol L-1) Male  142 ± 2 143 ± 2 142 ± 4 143 ± 2 145 ± 3 
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 590 
 591 
 Female  144 ± 6 143 ± 3 147 ± 2 148 ± 5 150 ± 6 
Potassium (mmol L-1) Male  4.6 ± 0.1 4.8 ± 0.2 4.8 ± 1.1 4.7 ± 0.9 4.5 ± 2.1 
 Female  5.2 ± 0.9 4.6 ± 1.2 4.8 ± 0.9 4.7 ± 1.1 5 ± 1.6 
Ionized Calcium (mmol L-1)  Male  1.50  ± 0.1 1.50 ± 0.18 1.47 ± 0.24 1.37 ± 0.34 1.34 ± 0.60 
 Female 1.46 ± 0.22 1.50 ± 0.13 1.51 ± 0.19 1.43 ± 0.25 1.37 ± 0.34 
Chloride (mmol L-1) Male  110 ± 3 116 ± 4 116 ± 6 114 ± 6 117 ± 5 
 Female  114 ± 8 110 ± 4 116 ± 4 117 ± 7 114 ± 4 
Glucose (mmol L-1) Male  12.4 ± 3 7.1 ± 3.6 7.02 ± 3.1 5.8 ± 0.6 5.8 ± 2.8 
 Female  13 ± 2.5 7.8 ± 2.5 6.3 ± 3.2 5.4 ± 1 5.9 ± 3.9 
Lactate (mmol L-1) Male  1.1 ± 0.7 1.0 ± 0.2 1.0 ± 0.1 1.1 ± 0.2 0.6 ± 0.1 
 Female  1.0  ± 0.1 1.1 ± 0.4 1.0 ± 0.3 1.1 ± 0.6 0.6 ± 0.1 
Creatinine (µmol L-1) Male  20 ± 7 35 ± 16 28 ± 13 37 ± 13 33 ± 20 
 Female  27 ± 12 33 ± 14 29 ± 14 37 ± 19 34 ± 14 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
35
Derived variables reported by the EPOC analyzer (actual bicarbonate, total CO2, base excess of extra cellular fluid, base 592 
excess of blood, oxygen saturation, anion gap, anion gap potassium, haemoglobin) were calculated but are not included in the 593 
table. The baseline (-5 minute) samples were all measured under isoflurane (2% vaporizer setting) in N2O and O2. 594 
 595 
* denotes statistical difference between the groups (p<0.05). 596 
 597 
 598 
 599 
 600 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
 
 
Figure 1 Mean (± SD) alfaxalone plasma concentrations (ng mL-1) for 12 Sprague 
Dawley rats (6 female, 6 male) after intravenous administration of alfaxalone 1.67 mg 
kg -1 min -1 for 2.5 minutes followed by 0.75 mg  kg -1  min -1 alfaxalone for 120 
minutes using a one compartment infusion model.  
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Figure 2 Mean (± SD) arterial blood pressure (MAP) (mmHg) for 12 Sprague Dawley 
rats (6 female, 6 male) after intravenous administration of alfaxalone 1.67 mg  kg -1  
min -1 for 2.5 minutes followed by 0.75 mg  kg -1 min -1 alfaxalone for 120 minutes 
using a one compartment infusion model.  
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